- Home
- VCEL vs CGON Comparison
VCEL vs CGON Comparison
Compare VCEL & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- CGON
- Stock Information
- Founded
- VCEL 1989
- CGON 2010
- Country
- VCEL United States
- CGON United States
- Employees
- VCEL N/A
- CGON N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- CGON
- Sector
- VCEL Health Care
- CGON
- Exchange
- VCEL Nasdaq
- CGON NYSE
- Market Cap
- VCEL 2.1B
- CGON 2.1B
- IPO Year
- VCEL 1997
- CGON 2024
- Fundamental
- Price
- VCEL $40.15
- CGON $26.90
- Analyst Decision
- VCEL Strong Buy
- CGON Strong Buy
- Analyst Count
- VCEL 8
- CGON 10
- Target Price
- VCEL $62.00
- CGON $64.44
- AVG Volume (30 Days)
- VCEL 430.8K
- CGON 864.2K
- Earning Date
- VCEL 07-31-2025
- CGON 08-07-2025
- Dividend Yield
- VCEL N/A
- CGON N/A
- EPS Growth
- VCEL 521.85
- CGON N/A
- EPS
- VCEL 0.05
- CGON N/A
- Revenue
- VCEL $238,541,000.00
- CGON $662,000.00
- Revenue This Year
- VCEL $23.03
- CGON N/A
- Revenue Next Year
- VCEL $24.52
- CGON $25,206.93
- P/E Ratio
- VCEL $705.61
- CGON N/A
- Revenue Growth
- VCEL 14.80
- CGON 224.51
- 52 Week Low
- VCEL $37.39
- CGON $14.80
- 52 Week High
- VCEL $63.00
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- VCEL 44.33
- CGON 59.29
- Support Level
- VCEL $40.53
- CGON $25.51
- Resistance Level
- VCEL $43.57
- CGON $27.28
- Average True Range (ATR)
- VCEL 1.62
- CGON 1.01
- MACD
- VCEL -0.16
- CGON 0.02
- Stochastic Oscillator
- VCEL 28.65
- CGON 89.23
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.